The broader federal rescheduling of marijuana from Schedule I to Schedule III remains stalled in administrative proceedings following an 11-day evidentiary hearing that concluded in July 2026. Certain state-licensed medical marijuana and FDA-approved products were already moved to Schedule III by final rule in April 2026, but the wider proposal faces a procedural stay ordered by DEA Administrative Law Judge Derek Julius on September 29. Opposing parties cited a September GAO report documenting gaps in DEA and FDA written policies for the eight-factor scheduling analysis, prompting additional briefing with a government response due October 13. The ALJ recommendation and subsequent DEA administrator determination have no fixed timeline, leaving the outcome dependent on how the agency addresses the GAO findings and any further process extensions. Trader consensus reflects these delays and unresolved procedural questions as the dominant near-term constraints.